$TELA SEC Filings

Received 16,089 shares as a grant or award ($16.2K)

Received 19,801 shares as a grant or award ($20K)

On October 8, 2026, TELA Bio, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). As of September 8, 2026, the record date for the Special Meeting, there were 45,143,410 outstanding shares of the Company’...

On October 5, 2026, TELA Bio, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Mark...

MALVERN, PA, October 5, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug...

On September 28, 2026, TELA Bio, Inc. (the “Company”) entered into a Limited Consent to Credit Agreement and Guaranty (the “Limited Consent”) with Perceptive Credit Holdings V, LP, as administrative agent and collateral agent (the “Admin...

Bought 50,000 shares ($58.3K) · Bought 25,000 shares ($30.5K)

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Bought 25,000 shares ($25.5K) · Bought 50,000 shares ($52.9K)

Bought 12,500 shares ($8.31K)

Bought 15,000 shares ($10.5K)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.